Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-03-04

FDA Approved: DEXILANT — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Dexilant (dexlansoprazole) from Takeda Pharmaceuticals America, expanding or modifying its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dexilant (dexlansoprazole)

Snippet

SUPPL AP for DEXILANT (DEXLANSOPRAZOLE)